PubRank

Jeffrey F Moley

Author PubWeight™ 61.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009 10.20
2 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010 2.96
3 Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004 2.18
4 Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003 2.11
5 Neuroendocrine tumors. J Natl Compr Canc Netw 2012 1.91
6 Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 2002 1.82
7 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002 1.70
8 Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 2007 1.64
9 Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J Surg 2010 1.57
10 Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 2015 1.51
11 ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006 1.41
12 Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol 2014 1.39
13 Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery 2007 1.13
14 Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 2002 1.12
15 Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 2006 1.11
16 Risk factors affecting operative approach, conversion, and morbidity for adrenalectomy: a single-institution series of 402 patients. Surg Endosc 2013 1.06
17 Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 2007 1.05
18 Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg Endosc 2012 1.04
19 Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. Surgery 2006 1.02
20 Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am 2009 1.01
21 Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 2004 1.00
22 Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol 2010 0.98
23 Lymph node metastases in differentiated thyroid cancer under 2 cm. Surgery 2006 0.95
24 Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm 2008 0.95
25 Metastatic disease to the breast: the Washington University experience. World J Surg Oncol 2007 0.95
26 Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg 2002 0.93
27 Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 2005 0.92
28 Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery 2005 0.91
29 Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res 2012 0.90
30 Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases. J Clin Endocrinol Metab 2005 0.90
31 ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol 2006 0.88
32 Medullary thyroid cancer. Surg Oncol Clin N Am 2006 0.87
33 Adrenal myelolipoma: operative indications and outcomes. J Laparoendosc Adv Surg Tech A 2013 0.85
34 Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med 2004 0.83
35 Medullary thyroid carcinoma: management of lymph node metastases. Curr Treat Options Oncol 2005 0.83
36 Multiple endocrine neoplasia type 2: clinical manifestations and management. Cancer Treat Res 2010 0.82
37 Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence. Thyroid 2014 0.81
38 The role of surgery in cancer prevention. Curr Probl Surg 2010 0.81
39 Ultrasound facilitates minimally invasive parathyroidectomy in patients lacking definitive localization from preoperative sestamibi scan. Am J Surg 2007 0.79
40 Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: implications for screening. J Surg Oncol 2013 0.79
41 Outpatient minimally invasive parathyroidectomy using local/regional anesthesia: a safe and effective operative approach for selected patients. Surgery 2005 0.79
42 Hereditary medullary thyroid carcinoma in patients greater than 50 years old. Surgery 2004 0.78
43 Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw 2015 0.78
44 The RET Protooncogene. Cancer Treat Res 2010 0.78
45 Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005 0.77
46 Management of cervical nodal metastasis detected on I-131 scintigraphy after initial surgery of well-differentiated thyroid carcinoma. Surgery 2010 0.76
47 RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg 2008 0.76
48 A novel missense mutation in the MEN1 gene in a patient with multiple endocrine neoplasia type 1. Endocr Pract 2011 0.76
49 Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol 2014 0.75